Smith & Wesson Brands, Inc. Reports First Quarter Fiscal 2021 Financial Results
First Quarter Fiscal 2021 Consolidated Financial Highlights
- Quarterly net sales were
$278.0 million compared with$123.7 million for the first quarter last year, an increase of 124.8%. Firearms segment gross sales were$229.9 million , which included$1.0 million of inter-segment revenue, an increase of$134.4 million , or 140.9%, over the comparable quarter last year. Outdoor Products & Accessories segment gross sales were$50.6 million , which included$1.5 million of inter-segment revenue, an increase of$17.4 million , or 52.3%, over the comparable quarter last year. - Gross margin for the quarter was 42.0% compared with 38.7% for the comparable quarter last year.
- Quarterly GAAP net income was
$48.4 million , or$0.86 per diluted share, compared with a GAAP net loss of$(2.1) million , or$(0.04) per diluted share, for the comparable quarter last year. - Quarterly non-GAAP net income was
$54.9 million , or$0.97 per diluted share, compared with$1.7 million , or$0.03 per diluted share, for the comparable quarter last year. GAAP to non-GAAP adjustments for net income exclude costs related to the spin-off of the Outdoor Products & Accessories segment, COVID-19 related expenses, and other costs. For a detailed reconciliation, see the schedules that follow in this release. - Quarterly non-GAAP Adjusted EBITDAS was
$84.2 million , or 30.3% of net sales, compared with$17.5 million , or 14.1% of net sales, for the comparable quarter last year.
Smith continued, "With the successful spin-off of our Outdoor Products & Accessories segment last week, we have now returned to our heritage as a pure-play firearms company, with a focus on organic growth and returning excess capital to our stockholders. As such, our Board of Directors has authorized the company to declare a regular, quarterly cash dividend of
Conference Call and Webcast
The company will host a conference call and webcast today,
Reconciliation of
In this press release, certain non-GAAP financial measures, including "non-GAAP net income," "Adjusted EBITDAS," and "free cash flow" are presented. From time-to-time, the company considers and uses these supplemental measures of operating performance in order to provide the reader with an improved understanding of underlying performance trends. The company believes it is useful for itself and the reader to review, as applicable, both (1) GAAP measures that include (i) amortization of acquired intangible assets, (ii) transition costs, (iii) recall related expenses, (iv) the tax effect of non-GAAP adjustments, (v) COVID-19 expenses, (vi) net cash used in investing activities, (vii) interest expense, (viii) income tax expense, (ix) depreciation and amortization, and (x) stock-based compensation expenses; and (2) the non-GAAP measures that exclude such information. The company presents these non-GAAP measures because it considers them an important supplemental measure of its performance. The company's definition of these adjusted financial measures may differ from similarly named measures used by others. The company believes these measures facilitate operating performance comparisons from period to period by eliminating potential differences caused by the existence and timing of certain expense items that would not otherwise be apparent on a GAAP basis. These non-GAAP measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for the company's GAAP measures. The principal limitations of these measures are that they do not reflect the company's actual expenses and may thus have the effect of inflating its financial measures on a GAAP basis.
About
Safe Harbor Statement
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and we intend that such forward-looking statements be subject to the safe-harbor created thereby. Such forward-looking statements include, among others, our intent to pay a regular, quarterly cash dividend. We caution that these statements are qualified by important risks, uncertainties, and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, economic, social, political, legislative, and regulatory factors; the potential for increased regulation of firearms and firearm-related products; actions of social activists that could have an adverse effect on our business; the impact of lawsuits; the demand for our products; the state of the
Contact:
investorrelations@smith-wesson.com
(413) 747-3448
|
|||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||
(Unaudited) |
|||
As of: |
|||
|
|
||
(In thousands, except par value and share data) |
|||
ASSETS |
|||
Current assets: |
|||
Cash and cash equivalents |
$ 65,271 |
$ 125,398 |
|
Accounts receivable, net of allowances for credit losses of |
101,358 |
93,433 |
|
Inventories |
149,567 |
164,191 |
|
Prepaid expenses and other current assets |
11,015 |
8,838 |
|
Income tax receivable |
656 |
1,595 |
|
Total current assets |
327,867 |
393,455 |
|
Property, plant, and equipment, net |
156,785 |
157,417 |
|
Intangibles, net |
69,842 |
73,754 |
|
Goodwill |
83,605 |
83,605 |
|
Deferred income taxes |
2,396 |
2,396 |
|
Other assets |
17,674 |
18,334 |
|
|
$ 728,961 |
||
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||
Current liabilities: |
|||
Accounts payable |
$ 53,829 |
$ 39,196 |
|
Accrued expenses and deferred revenue |
49,987 |
64,602 |
|
Accrued payroll and incentives |
13,241 |
14,623 |
|
Accrued income taxes |
18,905 |
5,503 |
|
Accrued profit sharing |
5,877 |
2,414 |
|
Accrued warranty |
3,462 |
3,633 |
|
Total current liabilities |
145,301 |
129,971 |
|
Notes and loans payable, net of current portion |
24,311 |
159,171 |
|
Finance lease payable, net of current portion |
39,610 |
39,873 |
|
Other non-current liabilities |
11,882 |
12,828 |
|
Total liabilities |
221,104 |
341,843 |
|
Commitments and contingencies |
|||
Stockholders' equity: |
|||
Preferred stock, $.001 par value, 20,000,000 shares authorized, no shares issued or outstanding |
— |
— |
|
Common stock, $.001 par value, 100,000,000 shares authorized, 73,864,745 issued and 55,697,883 shares outstanding on |
74 |
74 |
|
Additional paid-in capital |
269,192 |
267,630 |
|
Retained earnings |
390,101 |
341,716 |
|
Accumulated other comprehensive income |
73 |
73 |
|
|
(222,375) |
(222,375) |
|
Total stockholders' equity |
437,065 |
387,118 |
|
|
$ 728,961 |
|
||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME/(LOSS) |
||||
(Unaudited) |
||||
For the Three Months Ended |
||||
|
|
|||
(In thousands, except per share data) |
||||
Net sales |
|
|
||
Cost of sales |
161,199 |
75,811 |
||
Gross profit |
116,766 |
47,854 |
||
Operating expenses: |
||||
Research and development |
2,965 |
3,229 |
||
Selling, marketing, and distribution |
19,269 |
16,773 |
||
General and administrative |
29,080 |
26,709 |
||
Total operating expenses |
51,314 |
46,711 |
||
Operating income |
65,452 |
1,143 |
||
Other income/(expense), net: |
||||
Other income/(expense), net |
151 |
5 |
||
Interest expense, net |
(1,316) |
(2,627) |
||
Total other (expense)/income, net |
(1,165) |
(2,622) |
||
Income/(loss) from operations before income taxes |
64,287 |
(1,479) |
||
Income tax expense |
15,902 |
629 |
||
Net income/(loss) |
$ 48,385 |
$ (2,108) |
||
Net income/(loss) per share: |
||||
Basic |
$ 0.87 |
$ (0.04) |
||
Diluted |
$ 0.86 |
$ (0.04) |
||
Weighted average number of common shares outstanding: |
||||
Basic |
55,494 |
54,783 |
||
Diluted |
56,277 |
54,783 |
|
|||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||
(Unaudited) |
|||
For the Three Months Ended |
|||
|
|
||
(In thousands) |
|||
Cash flows from operating activities: |
|||
Net income/(loss) |
$ 48,385 |
$ (2,108) |
|
Adjustments to reconcile net income/(loss) to net cash provided by/(used in) operating activities: |
|||
Depreciation and amortization |
12,888 |
14,346 |
|
Loss/(gain) on sale/disposition of assets |
3 |
— |
|
Provision for losses on notes and accounts receivable |
136 |
634 |
|
Stock-based compensation expense |
1,041 |
1,588 |
|
Changes in operating assets and liabilities: |
|||
Accounts receivable |
(6,811) |
14,031 |
|
Inventories |
14,624 |
(31,678) |
|
Prepaid expenses and other current assets |
(2,177) |
(2,822) |
|
Income taxes |
14,341 |
397 |
|
Accounts payable |
14,061 |
(6,015) |
|
Accrued payroll and incentives |
(1,382) |
(10,875) |
|
Accrued profit sharing |
3,463 |
686 |
|
Accrued expenses and deferred revenue |
(14,640) |
(6,675) |
|
Accrued warranty |
(171) |
(612) |
|
Other assets |
660 |
428 |
|
Other non-current liabilities |
(946) |
(463) |
|
Net cash provided by/(used in) operating activities |
83,475 |
(29,138) |
|
Cash flows from investing activities: |
|||
Payments to acquire patents and software |
(292) |
(123) |
|
Payments to acquire property and equipment |
(7,343) |
(3,695) |
|
Net cash used in investing activities |
(7,635) |
(3,818) |
|
Cash flows from financing activities: |
|||
Proceeds from loans and notes payable |
— |
25,000 |
|
Payments on finance lease obligation |
(238) |
(214) |
|
Payments on notes and loans payable |
(135,000) |
(1,575) |
|
Proceeds from exercise of options to acquire common stock |
268 |
— |
|
Payment of employee withholding tax related to restricted stock units |
(997) |
(538) |
|
Net cash (used in)/provided by financing activities |
(135,967) |
22,673 |
|
Net decrease in cash and cash equivalents |
(60,127) |
(10,283) |
|
Cash and cash equivalents, beginning of period |
125,398 |
41,015 |
|
Cash and cash equivalents, end of period |
$ 65,271 |
$ 30,732 |
|
Supplemental disclosure of cash flow information |
|||
Cash paid for: |
|||
Interest |
$ 1,556 |
$ 1,690 |
|
Income taxes |
$ 1,689 |
$ 235 |
|
|||||||
For the Three Months Ended |
|||||||
|
|
||||||
$ |
% of Sales |
$ |
% of Sales |
||||
GAAP gross profit |
|
42.0% |
$ 47,854 |
38.7% |
|||
Diode recall |
— |
— |
(589) |
-0.5% |
|||
COVID-19 |
1,109 |
0.4% |
— |
— |
|||
Transition costs |
— |
— |
620 |
0.5% |
|||
Non-GAAP gross profit |
|
42.4% |
$ 47,885 |
38.7% |
|||
GAAP operating expenses |
$ 51,314 |
18.5% |
$ 46,711 |
37.8% |
|||
Amortization of acquired intangible assets |
(4,094) |
-1.5% |
(4,770) |
-3.9% |
|||
Transition costs |
(3,595) |
-1.3% |
(466) |
-0.4% |
|||
COVID-19 |
(67) |
0.0% |
— |
— |
|||
Non-GAAP operating expenses |
$ 43,558 |
15.7% |
$ 41,475 |
33.5% |
|||
GAAP operating income |
$ 65,452 |
23.5% |
$ 1,143 |
0.9% |
|||
Diode recall |
— |
— |
(589) |
-0.5% |
|||
Amortization of acquired intangible assets |
4,094 |
1.5% |
4,770 |
3.9% |
|||
Transition costs |
3,595 |
1.3% |
1,086 |
0.9% |
|||
COVID-19 |
1,176 |
0.4% |
— |
— |
|||
Non-GAAP operating income |
$ 74,317 |
26.7% |
$ 6,410 |
5.2% |
|||
GAAP net income/(loss) |
$ 48,385 |
17.4% |
$ (2,108) |
-1.7% |
|||
Amortization of acquired intangible assets |
4,094 |
1.5% |
4,770 |
3.9% |
|||
Diode recall |
— |
— |
(589) |
-0.5% |
|||
Transition costs |
3,595 |
1.3% |
1,086 |
0.9% |
|||
COVID-19 |
1,176 |
0.4% |
— |
— |
|||
Tax effect of non-GAAP adjustments |
(2,394) |
-0.9% |
(1,422) |
-1.1% |
|||
Non-GAAP net income |
$ 54,856 |
19.7% |
$ 1,737 |
1.4% |
|||
GAAP net income/(loss) per share - diluted |
$ 0.86 |
$ (0.04) |
|||||
Amortization of acquired intangible assets |
0.07 |
0.09 |
|||||
Diode recall |
— |
(0.01) |
|||||
Transition costs |
0.06 |
0.02 |
|||||
COVID-19 |
0.02 |
— |
|||||
Tax effect of non-GAAP adjustments |
(0.04) |
(0.03) |
|||||
Non-GAAP net income per share - diluted |
$ 0.97 |
$ 0.03 |
|
|||
RECONCILIATION OF NET OPERATING CASH FLOW TO FREE CASH FLOW |
|||
For the Three Months Ended |
|||
|
|
||
Net cash provided by/(used in) operating activities |
$ 83,475 |
$ (29,138) |
|
Net cash used in investing activities |
(7,635) |
(3,818) |
|
Free cash flow |
$ 75,840 |
$ (32,956) |
|
||||
RECONCILIATION OF GAAP NET INCOME/(LOSS) TO NON-GAAP ADJUSTED EBITDAS |
||||
For the Three Months Ended |
||||
|
|
|||
GAAP net income/(loss) |
$ 48,385 |
$ (2,108) |
||
Interest expense |
1,357 |
2,763 |
||
Income tax expense |
15,902 |
629 |
||
Depreciation and amortization |
12,748 |
14,092 |
||
Stock-based compensation expense |
1,041 |
1,588 |
||
COVID-19 |
1,176 |
— |
||
Transition costs |
3,595 |
1,086 |
||
Diode recall |
— |
(589) |
||
Non-GAAP Adjusted EBITDAS |
$ 84,204 |
$ 17,461 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/smith--wesson-brands-inc-reports-first-quarter-fiscal-2021-financial-results-301124151.html
SOURCE